Neratinib Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Neratinib Therapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6596/720_v2_Neratinib.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. 6

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HSE (1) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib
HSE (1) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HSE (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
HSE (1) ER positive, ERBB2 amplification Invasive Breast Carcinoma Neratinib
HSE (1) ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib